Compare RC & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RC | AUTL |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United Kingdom |
| Employees | 442 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.3M | 431.2M |
| IPO Year | N/A | 2025 |
| Metric | RC | AUTL |
|---|---|---|
| Price | $1.75 | $1.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $2.81 | ★ $8.50 |
| AVG Volume (30 Days) | 1.7M | ★ 1.8M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $84.74 |
| Revenue Next Year | $67.36 | $65.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $1.50 | $1.15 |
| 52 Week High | $4.75 | $2.70 |
| Indicator | RC | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 57.09 | 62.66 |
| Support Level | $1.65 | $1.25 |
| Resistance Level | $2.15 | $1.69 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 94.00 | 98.74 |
Ready Capital Corp is a real estate finance company that originates, acquires, finances, and services LMM loans, SBA loans, construction loans, USDA loans and, to a lesser extent, MBS collateralized mainly by LMM loans or other real estate-related investments. Its loans are used by businesses to purchase real estate used in their operations or by investors seeking to acquire multi-family, office, retail, mixed use or warehouse properties. It operates through two segments: LMM Commercial Real Estate, which originates LMM loans across the life-cycle of an LMM property including construction, bridge, stabilized and agency loan channels, and Small Business Lending, which acquires, originates and services owner-occupied loans guaranteed by the SBA and also originates and services USDA loans.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.